SCHEMBL4673793

SCHEMBL4673793

O=C(C=C(O)c1nn[nH]n1)c1cc(CCc2ccccc2)cn1S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.38
NCEH1 Q6PIU2 1/20 0.38
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
PTGDR2 Q9Y5Y4 3/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PTGS2 P35354 2/20 0.34
PKM P14618 2/20 0.34
ALDH3A1 P30838 1/20 0.33
LMNA P02545 1/20 0.33
HTR6 P50406 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
NOD2 Q9HC29 1/20 0.32
NOD1 Q9Y239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674121 0.91 TBXA2R (0.39) CES1NCEH1ALDH1A1GAAMEN1
SCHEMBL4674859 0.89 NOD2 (0.35) PTGDR2CYP2C8CYP2C9CYP2C19LMNA
SCHEMBL4673689 0.86 SGMS1 (0.35) ALDH1A1GAAMEN1HPGDKMT2A
SCHEMBL4674175 0.85 PTGDR2 (0.34) KMT2APTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL4678991 0.84 RORC (0.33) KMT2APTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL4677953 0.83 CES1 (0.40) CES1NCEH1KMT2A
SCHEMBL4679976 0.81 CES1 (0.37) CES1NCEH1ALDH1A1GAAMEN1
SCHEMBL4672034 0.81 PTGDR2 (0.34) KMT2APTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL4674741 0.81 PPME1 (0.38) MEN1KMT2APKMALDH3A1HTR6
SCHEMBL4676526 0.81 KMT2A (0.32) KMT2APTGDR2CYP2C8CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.